Effects of initial ART regimen on death among HIV patients who initiated ART between 2011 and 2013 in Guangxi, China, by initial ART regimen
| Variable | No | Deaths | Person-years | Deaths/100 person-years (95% CI) | AHR* (95% CI) | P values | AHR* (95% CI) | P values |
| Total | 25 732 | 2062 | 78 137.47 | 2.64 (2.53 to 2.75) | ||||
| Initial ART regimen | ||||||||
| D4T-based regimen | 5483 | 656 | 17 384.21 | 3.77 (3.48 to 4.06) | Reference | |||
| AZT-based regimen | 12 018 | 695 | 38 705.61 | 1.80 (1.66 to 1.93) | 0.65 (0.58 to 0.73) | <0.001 | Reference | |
| TDF-based regimen | 5352 | 388 | 14 315.82 | 2.71 (2.44 to 2.98) | 0.81 (0.71 to 0.92) | 0.001 | 1.24 (1.10 to 1.41) | <0.001 |
| LPV/r-based regimen | 2879 | 323 | 7731.82 | 4.18 (3.72 to 4.63) | 1.19 (1.04 to 1.37) | 0.01 | 1.83 (1.60 to 2.10) | <0.001 |
*AHR, covariates of the adjusted model included: age, sex, marital status, route of HIV infection, CD4 count before ART, WHO clinic stage before ART.
AHR, adjusted HR; ART, antiretroviral therapy; AZT, zidovudine; D4T, stavudine; LPV/r, lopinavir–ritonavir; TDF, tenofovir.